Twist Bioscience (NASDAQ:TWST) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Twist Bioscience (NASDAQ:TWST - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09, Zacks reports. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same quarter last year, the firm posted ($0.75) EPS. The firm's revenue for the quarter was up 24.1% on a year-over-year basis. Twist Bioscience updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.

Twist Bioscience Stock Up 0.1 %

NASDAQ TWST traded up $0.04 on Thursday, reaching $53.70. The stock had a trading volume of 1,056,961 shares, compared to its average volume of 792,873. Twist Bioscience has a 12-month low of $27.41 and a 12-month high of $60.90. The stock has a fifty day moving average price of $48.84 and a two-hundred day moving average price of $46.32. The firm has a market capitalization of $3.19 billion, a price-to-earnings ratio of -14.92 and a beta of 1.87.

Analysts Set New Price Targets

Several research firms have recently weighed in on TWST. Barclays decreased their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday. Robert W. Baird upped their price target on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday. TD Cowen reiterated a "buy" rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $53.80.

Insider Activity at Twist Bioscience

In related news, COO Patrick John Finn sold 10,340 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00. Following the completion of the transaction, the chief operating officer now owns 221,061 shares in the company, valued at approximately $10,610,928. The trade was a 4.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 7,968 shares of the firm's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $382,464.00. Following the completion of the sale, the chief executive officer now owns 581,584 shares in the company, valued at approximately $27,916,032. This represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 59,002 shares of company stock worth $2,851,681. Corporate insiders own 3.01% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.